157 related articles for article (PubMed ID: 38602224)
1. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.
Senhaji-Kacha A; Akir A; Broncano-Lavado A; Esteban J
Rev Esp Quimioter; 2024 Jun; 37(3):266-269. PubMed ID: 38602224
[TBL] [Abstract][Full Text] [Related]
2.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
3. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
4. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
[No Abstract] [Full Text] [Related]
5. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
[TBL] [Abstract][Full Text] [Related]
6. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates.
Nie W; Duan H; Huang H; Lu Y; Chu N
Biomed Res Int; 2015; 2015():506598. PubMed ID: 26146620
[TBL] [Abstract][Full Text] [Related]
7. Cumulative antimicrobial susceptibilities for respiratory clinical isolates of
Shakoor S; Shafiq S; Shahid A; Mir F; Ali R; Hasan R
Int J Mycobacteriol; 2023; 12(3):310-315. PubMed ID: 37721238
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E;
J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340
[TBL] [Abstract][Full Text] [Related]
9.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
12.
Sun Q; Liao X; Wang C; Jiang G; Yang J; Zhao J; Huang H; Wang G; Li H
J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708979
[No Abstract] [Full Text] [Related]
13. Improved Performance Predicting Clarithromycin Resistance in
Lipworth S; Hough N; Buchanan R; Smith EG; Robinson E; Alexander E; Peto T; Crook D; Walker T
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160290
[No Abstract] [Full Text] [Related]
14. Drug susceptibility profiles and factors associated with non-tuberculous mycobacteria species circulating among patients diagnosed with pulmonary tuberculosis in Tanzania.
Maya TG; Komba EV; Mensah GI; Mbelele PM; Mpagama SG; Mfinanga SG; Addo KK; Kazwala RR
PLoS One; 2022; 17(3):e0265358. PubMed ID: 35324922
[TBL] [Abstract][Full Text] [Related]
15.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
[TBL] [Abstract][Full Text] [Related]
16. Implication of species change of Nontuberculous Mycobacteria during or after treatment.
Lee JS; Lee JH; Yoon SH; Kim TS; Seong MW; Han SK; Yim JJ
BMC Pulm Med; 2017 Dec; 17(1):213. PubMed ID: 29262802
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Efficacy of Free and Nanoparticle Formulations of Gallium(III) meso-Tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and Gallium Biodistribution in Mice.
Choi SR; Britigan BE; Switzer B; Hoke T; Moran D; Narayanasamy P
Mol Pharm; 2018 Mar; 15(3):1215-1225. PubMed ID: 29421865
[TBL] [Abstract][Full Text] [Related]
18. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
19. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
Chu HS; Chang SC; Shen EP; Hu FR
PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
[TBL] [Abstract][Full Text] [Related]
20. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.
Greendyke R; Byrd TF
Antimicrob Agents Chemother; 2008 Jun; 52(6):2019-26. PubMed ID: 18378709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
